Replimune (REPL) Cash from Financing Activities (2018 - 2026)

Replimune (REPL) reported Cash from Financing Activities of $55.7 million for Q1 2026, up 42279.55% on a YoY basis from N/an in Q1 2025, and up 432.74% sequentially from $10.5 million in Q4 2025.

Replimune (REPL) Cash from Financing Activities (2018 - 2026) Analysis & Trends

Replimune (REPL) has 9 years of Cash from Financing Activities data on file, last reported at $55.7 million in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Financing Activities rose 42279.55% year-over-year to $55.7 million; the trailing twelve-month figure through Mar 2026 stood at $66.3 million (down 73.73% YoY), and the FY2026 full-year result was $66.3 million, down 73.73% from the prior year.
  • Cash from Financing Activities advanced to $55.7 million in Q1 2026, from $10.5 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $271.4 million in Q4 2022 to a low of -$158000.0 in Q2 2025.
  • A 5-year average of $38.0 million and a median of $1.1 million in 2023 frame the typical range for Cash from Financing Activities.
  • Across the five-year window, Cash from Financing Activities slumped 121.45% in 2023 and soared 42279.55% in 2026, its largest moves.
  • Tracing REPL's Cash from Financing Activities over 5 years: stood at $271.4 million in 2022, then slumped by 94.52% to $14.9 million in 2023, then soared by 948.62% to $155.9 million in 2024, then plunged by 93.3% to $10.5 million in 2025, then soared by 432.74% to $55.7 million in 2026.
  • Business Quant data shows REPL's Cash from Financing Activities at $55.7 million in Q1 2026, $10.5 million in Q4 2025, and $324000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 30.14 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 68.63 Mn
4 NuCana 279.75 Bn 279.75 Bn - 9,311.16
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 238.74 Mn
10 Replimune 970.73 Mn 970.73 Mn - 55.68 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 55.68 Mn
Mar 31, 2026 55.68 Mn
Dec 31, 2025 10.45 Mn
Dec 31, 2025 10.45 Mn
Sep 30, 2025 324,000.00
Sep 30, 2025 324,000.00
Jun 30, 2025 -158,000.00
Jun 30, 2025 -158,000.00
Mar 31, 2025 -132,000.00
Mar 31, 2025 -132,000.00
Dec 31, 2024 155.93 Mn
Dec 31, 2024 155.93 Mn
Sep 30, 2024 -39,000.00
Sep 30, 2024 -39,000.00
Jun 30, 2024 96.64 Mn
Jun 30, 2024 96.64 Mn
Mar 31, 2024 -130,000.00
Mar 31, 2024 -130,000.00
Dec 31, 2023 14.87 Mn
Dec 31, 2023 14.87 Mn